Losartan treating podocyte injury induced by Ang II via downregulation of TRPC6 in podocytes.
In this study, we investigated the molecule mechanisms of podocyte injury and proteinuria and the protective effects of losartan. This study set up three groups: a control group; an Ang II group (Ang II 10(-6) mol/l, Sigma); and a losartan group (losartan 10(-6) mol/l, Sigma). We used RT-PCR assay to detect TRPC6 mRNA expression, and Western blot to detect TRPC6 protein expression. TRPC6 overexpression was the basic change of podocyte injury and proteinuria occurrence. Losartan can treat podocyte injury and proteinuria induced by Ang II via downregulation of TRPC6 in podocytes. These findings maybe provide an ideal drug target for the diagnosis and treatment of acquired glomerular diseases.